Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive advanced stage non-small-cell lung cancer

Faculty	Medicine	Year:	2018
Type of Publication:	ZU Hosted	Pages:
Authors:
Journal:	Cancer Management and Research DOVE MEDICAL PRESS LTD	Volume:

Keywords :	Efficacy , safety , crizotinib , patients with anaplastic
Abstract:	Lung cancer is the leading cause of cancer mortality worldwide, despite advances in management, especially with targeted agents and immunotherapy. Numerous oncogenes have been identified that control the growth of these malignancies. Anaplastic lymphoma kinas (ALK) is a tyrosine kinase that develops distorted functioning as a result of chromosomal rearrangement. Crizotinib, a tyrosine kinase inhibitor (TKI), was approved by the Food and Drug Administration (FDA) in 2011 for the treatment of advanced ALK-positive non-small-cell lung cancer (NSCLC). -In NSCLC, crizotinib is a viable treatment option with good response and tolerable toxicity for patients with ALK-positive advanced disease

Author Related Publications

Foad Mohamed Mohamed Abotaleb, "الاحتفاظ بالمثانة البولية فى سرطان الخلايا الانتقالية التوسعى عن طريق الاستئصال الجزئى عبر قناة مجرى البول والعلاج الكيميائى سى . أم . ف", لايوجد, 1900 More
Foad Mohamed Mohamed Abotaleb, "المضاعفات الكبدية التى تحدث بعد عملية زرع النخاع العظمى الذاتى لمرضى سرطان الغدد الليمفاوية الذين يحملون الاجسام المضادة لفيروس الالتهاب الكبدى الوبائى من النوع سى", لايوجد, 1900 More
Shereen Mostafa Saleh Elshorbagy, "- Detection of Paroxysmal Hemogloinuria Clones In patients With Pancytopenia", . IJAR 3,12,866-875; 2015, 2015 More
Shereen Mostafa Saleh Elshorbagy, "- CD19 and CD56 Antigens Expression in Acute Myeloid Leukemia Identifies Patients with Prognosis in Egypt Adverse", . IJSR 5; 2016, 2016 More
Ahmed Abdelrehem Ahmed Abdulrihem, "Significance of PAX (CDX2) gene expression in adult acute Myeloid leukemia", http://www.journalijar.com/, 2015 More